Blue Cross Blue Shield of North Dakota (BCBSND) regularly develops and revises pharmacy policies in response to rapidly changing pharmaceutical requirements. Our commitment is to update the provider community as pharmacy policies are adopted and/or revised.
The following medical drug policy is new:
The following medical drug policy has preferred product changes effective April 1, 2022:
The following medical drug policies were revised:
- Alpha1-Proteinase Inhibitors
- Chemodenervation with Botulinum Toxin
- Chimeric Antigen Receptor Therapy for Leukemia and Lymphoma
- Contraceptive Management
- Emicizumab-kxwh (Hemlibra)
- Fulvestrant (Faslodex)
- Givosiran (Givlaari)
- Implantable Hormone Replacement Pellets
- Lurbinectedin (Zepzelca)
- Luspatercept (Reblozyl)
- Obinutuzumab (Gazyva)
- Rituximab (Rituxan), Rituximab Biosimilars, and Rituximab and Hyaluronidase Human (Rituxan Hycela)
- Teprotumumab-trbw (Tepezza)
- Therapeutic Radiopharmaceuticals in Oncology
The following medical drug policy had a coding change effective January 1, 2022:
The following medical drug policies were reviewed with no clinical content change:
- Bendamustine (Treanda, Bendeka, Belrapzo)
- Elosulfase alfa (Vimizim)
- Emapalumab-lzsg (Gamifant)
- Eptinezumab-jjmr (Vyepti)
- Intravitreal Implants
- Necitumumab (Portrazza)
- Pegaspargase (Oncaspar), Asparaginase Erwinia Chrysanthemi (Erwinaze), and Calaspargase Pegol-mknl (Asparlas)
- Pertuzumab, trastuzumab, and hyaluronidase-zzxf (Phesgo)
The following medical drug policies were revised specifically for Medicaid Expansion:
Note: There may be corresponding policies for our Commercial lines of business or policies that apply to both Commercial and Medicaid Expansion lines of business.
